rogermontgomery - why-we-continue-to-like-sirtex/, page-11

My takeaway from the article was that the addressable market for srx has (even if trial results are not as positive as anticipated) increased due to:

1. Increase in the addressable market due to the salvage market expanding more than initially anticipated.
2. Treatment options being tailored for individuals specifically.

I dont think this was part of their thesis when they first invested in srx. Also I believe David Buckland brought over a great deal of knowledge about srx from his time at hunter hall, but he is CEO so this has obviously been passed down to the analysts.